Patents Examined by Catherine S Hibbert
  • Patent number: 10793921
    Abstract: The present invention is directed to a cellular biosensor system comprising (A) a repressor module comprising one or more genes, which in their cumulative gene action exert repressing and/or inhibitory effect(s) on (B), an output module comprising at least one gene comprising at least one output sequence generating one or more output signals (i) in the absence of repressing and/or inhibitory effect(s) of the repressor module (A) and (ii) in the presence of at least one recombinase expressed by (C), a recombinase module comprising at least one gene comprising at least one sequence encoding a site-specific recombinase that enables gene rearrangement in the output module resulting in one or more output signals in the absence of repressing and/or inhibitory effect(s) of the repressor module, wherein the repressing and/or inhibitory effects of the repressor module are controlled by one or more inputs that negatively affect the repressing and/or inhibitory effects of the repressor module (A).
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: October 6, 2020
    Assignee: ETH ZURICH
    Inventors: Yaakov Benenson, Nicolas Lapique
  • Patent number: 10787662
    Abstract: Provided herein are methods and compositions to make guide nucleic acids (gNAs), nucleic acids encoding gNAs, collections of gNAs, and nucleic acids encoding for a collection of gNAs from any source nucleic acid. Also provided herein are methods and compositions to use the resulting gNAs, nucleic acids encoding gNAs, collections of gNAs, and nucleic acids encoding for a collection of gNAs in a variety of applications.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: September 29, 2020
    Assignee: ARC BIO, LLC
    Inventor: Stephane B. Gourguechon
  • Patent number: 10786564
    Abstract: Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: September 29, 2020
    Assignees: NATIONAL HEALTH RESEARCH INSTITUTES, FUJIFILM IRVINE SCIENTIFIC, INC.
    Inventors: Jenny Bang, Hsiao-Tzu Ni, Alan Yung-Chih Hu, Tsai-Chuan Weng
  • Patent number: 10787644
    Abstract: Methods and compositions for rapid development of reporter lines utilizing safe harbor sites in iPSCS, as well as other progenitor cells, pluripotent and multipotent stem cells and differentiated cells, and multiple Lox sites are provided.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: September 29, 2020
    Assignee: RXCELL INC.
    Inventors: Xianmin Zeng, Mahendra S. Rao
  • Patent number: 10781432
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: September 22, 2020
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Patent number: 10774365
    Abstract: Provided herein are methods and compositions for depleting targeted nucleic acid sequences from a sample, enriching for sequences of interest from a sample, and/or partitioning of sequences from a sample. The methods and compositions are applicable to biological, clinical, forensic, and environmental samples.
    Type: Grant
    Filed: December 19, 2015
    Date of Patent: September 15, 2020
    Assignee: ARC BIO, LLC
    Inventors: Meredith L. Carpenter, Carlos D. Bustamante, Stephane B. Gourguechon
  • Patent number: 10767194
    Abstract: Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a nuclease-null Cas9 protein that binds to the DNA and is guided by the one or more RNAs, introducing into the cell a third foreign nucleic acid encoding a transcriptional regulator protein or domain, wherein the one or more RNAs, the nuclease-null Cas9 protein, and the transcriptional regulator protein or domain are expressed, wherein the one or more RNAs, the nuclease-null Cas9 protein and the transcriptional regulator protein or domain co-localize to the DNA and wherein the transcriptional regulator protein or domain regulates expression of the target nucleic acid.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 8, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Prashant G. Mali, Kevin M. Esvelt
  • Patent number: 10760071
    Abstract: A system for continuous mutagenesis to facilitate directed evolution, the system including DNA polymerases carrying the novel K54E point mutation, and other point mutations including I709N, A759R, D424A (herein called K54E_LF Pol I) and this methods of use to produce and detect lines where mutagenesis is continuous and does not exhibit the usual decline in mutagenesis with sequential cloning.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 1, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Manel Camps
  • Patent number: 10760081
    Abstract: Provided are approaches to improving CRISPR-based DNA editing by performing the editing in cells in which pol ? (“POLQ”) enzyme and/or its function is reduced. Approaches are provided that are applicable to Cas9 nuclease and Cas9 nickase CRISPR editing. Also provided are kits that can contain a polynucleotide encoding a Cas9 and an agent for use in inhibiting POLQ, and/or or an expression vector configured for expressing a mutation template for use in CRISPR chromosome editing and an agent for use in inhibiting POLQ.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: September 1, 2020
    Assignee: New York University
    Inventors: Agnel Sfeir, Pedro Mateos-Gomez
  • Patent number: 10752674
    Abstract: The present disclosure relates to a method of obtaining a cell where fucosylation pathways are modified, leading to production of partially fucosylated and non-fucosylated protein products, specifically antibodies from the cell. The present disclosure employs the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. The method of the present disclosure targets the Fut8 gene and GMD gene in a cell. Such products are used in developing therapeutics and biomarkers, and in diagnosis and prognosis of diseases.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 25, 2020
    Assignee: Zumutor Biologics Inc.
    Inventors: Bhargav Prasad, Divya Unnikrishnan, Jahnabi Hazarika, Kavitha Iyer Rodrigues, Maloy Ghosh, Pavithra M, Pravin Kumar D, Sanghamitra Bhattacharjee, Sathyabalan M, Sankaranarayanan Srinivasan, Sohang Chatterjee, Sunit Maity, Veeresha K, Vivek Halan, Yogendra Manjunath B. M., Anuradha Hora, Bairavabalakumar N, Karthika Nair, Aswini Thanigaivel, Amol Maliwalave, Bharath R Shenoy, Rajeshwari Pendse, Prabhat Kumar Pathak, Anisha Kurup, Sahana Bhima Rao
  • Patent number: 10745717
    Abstract: The invention relates to a vector comprising: a 5? nucleic acid that is homologous to a genomic sequence 5? of a stop codon of a constitutively expressed gene; an exogenous nucleic acid; a 3? nucleic acid that is homologous to a genomic sequence 3? of the stop codon of the constitutively expressed gene; a translation interruption-reinitiation signal operably linked to the 5? nucleic acid and the exogenous nucleic acid, wherein the translation interruption-reinitiation signal is capable of replacing the stop codon of the constitutively expressed gene.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: August 18, 2020
    Assignee: Murdoch Children's Research Institute
    Inventors: Ed Stanley, Andrew Elefanty, David Elliott, Tatiana Labonne
  • Patent number: 10731153
    Abstract: The disclosure provides novel large serine recombinases and their respective recognition sites, as well as libraries of orthogonal recombinase recognition sites. Uses of the large serine recombinases, recognition sites, and libraries of orthogonal recombinase recognition sites also are provided.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: August 4, 2020
    Assignees: Massachusetts Institute of Technology, INRIA (French Institute for Research in Computer Science and Automation)
    Inventors: Ron Weiss, Xavier Cesar Duportet, Gregory Batt, Yinqing Li
  • Patent number: 10724030
    Abstract: The present invention provides a system for delivering a time-varying stimulation field to a subject. In the system, a power source, a control component and a transmission component operate as a stimulation field generator to provide a predetermined time-varying stimulation field to up-regulate or down-regulate an expression level of human genes. The present invention also provides a wearable apparatus for delivering the time-varying magnetic field to mammalian cells associated with bone formation in a subject. The wearable apparatus contains the stimulation field generator in a housing. The resulted modification on gene regulation of these genes and mammalian cells promotes the retention, repair of and reduction of compromised mammalian cartilage, bone, and associated tissue.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: July 28, 2020
    Assignee: United States of America as Represented by the Administrator of the National Aeronautics and Space Administration
    Inventors: Thomas J. Goodwin, Linda C. Shackelford
  • Patent number: 10724051
    Abstract: A gene of interest and the gene encoding hypoxanthine-aminopterin-thymidine (HPRT) can be co-targeted for Casp9 nuclease-mediated editing or alteration in a cell. Based on whether the HPRT gene is altered to encode a non-functional protein, or is not so-altered, the co-targeted cells can be selected and counter-selected. HPRT co-targeting can be used to sequentially disrupt as many genes of interest as cell viability permits.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 28, 2020
    Assignee: Institute For Cancer Research
    Inventors: Hong Yan, Shuren Liao
  • Patent number: 10724033
    Abstract: A method for selecting mammalian host cells that express a polypeptide of interest with high yield is described. The host cells comprise an expression cassette comprising at least a first polynucleotide encoding the polypeptide of interest, at least one leaky stop codon downstream of the first polynucleotide, and a second polynucleotide downstream of the leaky stop codon encoding an immunoglobulin transmembrane anchor. The host cells are cultivated to allow expression of the polypeptide of interest such that at least a portion of the polypeptide of interest is expressed as a fusion polypeptide that is displayed on the cell surface. The cells are selected based upon the presence or amount of the displayed fusion polypeptide. Also provided are methods for producing a polypeptide that employ a respective selection to identify high expressing host cells.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: July 28, 2020
    Assignee: Novartis AG
    Inventors: Thomas Jostock, Hans-Peter Knopf, Burkhard Wilms, Audrey Nommay
  • Patent number: 10724043
    Abstract: Systems and methods are provided for transfecting immune competent cells with RNA at high efficiency and viability.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 28, 2020
    Assignee: NantBio, Inc.
    Inventors: Marcos Sixto, Kayvan Niazi, Ting Wu, Chihwei Chang
  • Patent number: 10717982
    Abstract: The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E. coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: July 21, 2020
    Assignees: BioNTech RNA Pharmaceuticals GmbH, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
    Inventors: Florian Eberle, Ugur Sahin, Andreas Kuhn, Britta Vallazza, Mustafa Diken
  • Patent number: 10718755
    Abstract: A method for screening a pharmaceutical compound for prevention, alleviation and/or treatment of steatohepatitis, the method including employing N-terminal dimerization of an apoptosis signal-regulated kinase 1 as a target.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: July 21, 2020
    Assignee: WUHAN UNIVERSITY
    Inventor: Hongliang Li
  • Patent number: 10718001
    Abstract: Disclosed is a host cell for producing a recombinant peptide, polypeptide or protein of interest, wherein the host cell includes at least 2 copies of a nucleic acid sequence encoding a poison protein; and to the use thereof for producing peptides, polypeptides or proteins of interest.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: July 21, 2020
    Assignee: DELPHI GENETICS
    Inventors: Cedric Szpirer, Jonathan Cavrenne, Benjamin Michel
  • Patent number: 10711279
    Abstract: The present invention relates to new promoter sequences and uses thereof, in particular expression cassettes, vectors, and methods of expressing genes using the new promoters.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: July 14, 2020
    Assignee: SANDOZ AG
    Inventors: Wolfgang Ernst, Jens Pontiller, Friedemann Hesse, Haruthai Thaisuchat